Risk assessment for recurrent venous thrombosis

scientific article

Risk assessment for recurrent venous thrombosis is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1016/S0140-6736(10)60962-2
P698PubMed publication ID21131039

P50authorFrits RosendaalQ16319080
P2093author name stringSabine Eichinger
Paul Alexander Kyrle
P2860cites workHigh rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort studyQ81743014
Overweight, obesity, and the risk of recurrent venous thromboembolismQ81769586
Recurrence rate after a first venous thrombosis in patients with familial thrombophiliaQ81885362
Family history for venous thromboembolism and the risk for recurrenceQ82345821
The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolismQ82769283
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin timeQ83193158
Thrombophilia testing for prevention of recurrent venous thromboembolismQ24241821
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerQ28186303
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studiesQ28237512
Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic reviewQ33468803
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor XimelagatranQ33973559
Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized studyQ33988556
Clinical guidelines for testing for heritable thrombophiliaQ34096556
Antithrombotic therapy for venous thromboembolic diseaseQ34131105
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolismQ34179254
Genetic susceptibility to venous thrombosisQ34223106
Thrombophilia, clinical factors, and recurrent venous thrombotic eventsQ34419598
D-dimer testing to determine the duration of anticoagulation therapyQ34576728
Risk of major hemorrhage for outpatients treated with warfarinQ34751905
Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic reviewQ36445071
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.Q36550717
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapyQ36841584
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodiesQ37020336
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolismQ37288236
Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolismQ37741638
Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous ThrombosisQ41099975
A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism.Q41746170
Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolismQ43556960
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.Q43597590
Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.Q44196663
Extended oral anticoagulant therapy after a first episode of pulmonary embolism.Q44496670
Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolismQ44680678
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factorQ44852505
Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in childrenQ45050847
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolismQ45298422
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolismQ45877633
Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism.Q46014301
Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis.Q46123639
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trialQ46368145
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolismQ47247982
The risk of recurrent venous thromboembolism in men and womenQ47332296
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysisQ47351547
High plasma levels of factor VIII and risk of recurrence of venous thromboembolismQ48036239
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.Q50780747
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.Q50782352
High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.Q51127047
Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.Q51574600
Age at first venous thromboembolism and risk of recurrence: a prospective cohort study.Q51603817
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.Q51831890
New diagnostic strategies for pulmonary embolism.Q51888146
A prediction rule to identify low-risk patients with pulmonary embolism.Q51922063
Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients.Q53186557
Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.Q53354829
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.Q53361537
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.Q53374794
Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trialQ56786477
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective studyQ56989286
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophiliaQ57003501
The Risk of Recurrent Venous Thromboembolism in Patients with an Arg506→Gln Mutation in the Gene for Factor V (Factor V Leiden)Q61657715
Long-term outcomes of deep-vein thrombosisQ72231512
The management of thrombosis in the antiphospholipid-antibody syndromeQ72619159
A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trialQ73180786
Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factorsQ73592975
The risk of recurrent venous thromboembolism among patients with high factor IX levelsQ73691028
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort studyQ73836575
D-dimer levels and risk of recurrent venous thromboembolismQ73864376
High plasma levels of factor VIII and the risk of recurrent venous thromboembolismQ74197149
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolismQ78670334
Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimerQ79696092
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patientsQ79765195
Pulmonary embolismQ79954098
Incidence and mortality of venous thrombosis: a population-based studyQ79969827
High-density lipoprotein and the risk of recurrent venous thromboembolismQ79985834
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generationQ79989153
Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolismQ80111833
Genetic variation in heme oxygenase 1 (HMOX1) and the risk of recurrent venous thromboembolismQ80507637
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) studyQ81322442
Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosisQ81425221
Deep vein thrombosisQ81584045
The post-thrombotic syndrome: risk factors and impact on the course of thrombotic diseaseQ81636022
P433issue9757
P407language of work or nameEnglishQ1860
P921main subjectthrombosisQ261327
P304page(s)2032-2039
P577publication date2010-12-03
P1433published inThe LancetQ939416
P1476titleRisk assessment for recurrent venous thrombosis.
P478volume376

Reverse relations

cites work (P2860)
Q344360612014 ESC guidelines on the diagnosis and management of acute pulmonary embolism
Q41874126A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan ~ usefulness of next generation sequencing~.
Q37368820A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis
Q26776112Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
Q26783455Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review
Q33841714Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism
Q53741293CDC Grand Rounds: preventing hospital-associated venous thromboembolism.
Q38808401Cardiovascular fitness in young males and risk of unprovoked venous thromboembolism in adulthood
Q60949185Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome
Q43703844Clinical presentation of venous thromboembolism in inflammatory bowel disease
Q47129005Combined Thrombophilia in a Young Male Presenting as Life Threatening Pulmonary Embolism
Q58108078Cost-effectiveness of alternative anticoagulation strategies for postoperative management of total knee arthroplasty patients
Q64936707Current and future burden of venous thrombosis: Not simply predictable.
Q37648653D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model.
Q38777416Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism.
Q47828398Effects of magnesium sulphate on coagulation after laparoscopic colorectal cancer surgery, measured by rotational thromboelastometry (ROTEM® ).
Q55252767Elevated leptin and decreased adiponectin independently predict the post-thrombotic syndrome in obese and non-obese patients.
Q37370722Epidemiology of recurrent venous thrombosis
Q41667853Epidemiology of venous thromboembolism
Q89002090Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism
Q37874154Estrogen and thrombosis: controversies and common sense
Q45870309External validation of the DASH prediction rule: a retrospective cohort study.
Q43468383Family history of venous thromboembolism (VTE) and risk of recurrent hospitalization for VTE: a nationwide family study in Sweden
Q47554769Fat mass and obesity-associated gene rs9939609 polymorphism is a potential biomarker of recurrent venous thromboembolism in male but not in female patients
Q35153652HIV-Associated Venous Thromboembolism
Q34305696Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study
Q40596897Hospital-related first venous thromboembolism and risk of recurrence
Q51220285Identification of Genetic Aberrations in Thrombomodulin Gene in Patients With Recurrent Venous Thromboembolism.
Q35890411Impact of Inherited Prothrombotic Disorders on the Long-Term Clinical Outcome of Percutaneous Transluminal Angioplasty in Patients with Diabetes.
Q44446974Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis.
Q36589493Inherited genetic markers for thrombophilia in northeastern Iran (a clinical-based report).
Q38992105Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow-up study.
Q47728750Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
Q26749273Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis
Q36718482Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach
Q26830769Managing pulmonary embolism using prognostic models: future concepts for primary care
Q35948292Medical management of venous thromboembolism: what the interventional radiologist needs to know
Q89529700Oral Intake of EPA:DHA 6:1 by Middle-Aged Rats for One Week Improves Age-Related Endothelial Dysfunction in Both the Femoral Artery and Vein: Role of Cyclooxygenases
Q38095148Overview and assessment of risk factors for pulmonary embolism
Q36842832Perioperative management of patients on chronic antithrombotic therapy
Q33431611Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial
Q57172953Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner
Q40989421Portomesenteric venous thrombosis as a rare cause of acute abdomen in a young patient: What should be the process of diagnosis and management?
Q38214962Predicting recurrent venous thromboembolism in cancer: is it possible?
Q92905420Predicting the risk of recurrent venous thrombosis: What the future might bring
Q26865059Predicting the risk of venous thromboembolism recurrence
Q34512379Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study
Q95560997Preparation, characterization and in vitro thrombolytic activity of a novel streptokinase foam
Q41458663Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening
Q36527065Prothrombotic gene variants as risk factors of acute myocardial infarction in young women
Q38001827Pulmonary embolism and deep vein thrombosis
Q64228949Re-Examining Genetic Screening and Oral Contraceptives: A Patient-Centered Review
Q33734478Recurrent Deep Vein Thrombosis After the First Venous Thromboembolism Event: A Single-Institution Experience.
Q64115907Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease
Q50660439Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study.
Q83725478Risk assessment for recurrent venous thrombosis
Q95474827Risk assessment for recurrent venous thrombosis
Q95474835Risk assessment for recurrent venous thrombosis
Q57183433Risk factors for post-thrombotic syndrome in patients with deep vein thrombosis: from the COMMAND VTE registry
Q64905654Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction.
Q30889099Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data
Q92681540Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
Q40499885Role of family history of venous thromboembolism and thrombophilia as predictors of recurrence: a prospective follow-up study
Q36735715Role of genetic changes in the progression of cardiovascular diseases
Q24197581Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Q47304199Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Q34525565Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE.
Q36032737Taller women are at greater risk of recurrent venous thromboembolism: the Iowa Women's Health Study
Q61815014Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events
Q36688746The Frequency of Some Thrombophilic Mutations in Eastern Turkey
Q36445585The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs
Q28067893The epidemiology of venous thromboembolism
Q36987388The impact of the DoH Commissioning for Quality and Innovation incentive on the success of venous thromboembolism risk assessment in hospitalised patients. A single institution experience in a quality outcome improvement over a 4-year cycle
Q51785468The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
Q38250865The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism
Q40993089Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism
Q30562555Unusual venous thrombosis in a 35-year-old man.
Q91632100Venous thromboembolism in inflammatory bowel disease
Q35825548Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.
Q82065973[Treatment of deep vein thrombosis and pulmonary embolism]